Xianglei Fu
Overview
Explore the profile of Xianglei Fu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
87
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhou J, Lin G, Fu X, Qiu S, Zhang Y, Chen X, et al.
ACS Appl Mater Interfaces
. 2025 Mar;
PMID: 40079695
The primary clinical challenges associated with postoperative maxillofacial osteosarcoma include high mortality rates and significant local recurrence. Additionally, patients often exhibit substantial bone defects that are incapable of self-healing, necessitating...
2.
Shi S, Wu Z, Huang Y, Fu X
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue
. 2025 Feb;
37(2):160-164.
PMID: 40017364
Objective: To explore the prognostic value of C-reactive protein (CRP)/albumin (Alb) ratio combined with platelet count (PLT) and Glasgow coma score (GCS) in patients with heat stroke (HS). Methods: A...
3.
Liu Y, Shen H, Zang H, Shi Y, Qiu S, Fu X, et al.
J Pharm Sci
. 2024 Dec;
114(2):1455-1463.
PMID: 39725228
In order to delay the progression of Rheumatoid Arthritis (RA) in patients, and to prevent further teratogenesis and irreversible bone erosion through drug intervention in the early stages of inflammation,...
4.
Chen X, Qiu S, Shi Y, Zang H, Li L, Fu X, et al.
Int J Pharm
. 2024 Sep;
666:124756.
PMID: 39341383
To prepare a PLGA microsphere loaded with the antipsychotic Blonanserin without release leg period and released in a near-zero model for long time, in this study, 15 kDa and 75 ...
5.
Qiu S, Shi Y, Zang H, Sun X, Wang Q, Fu X, et al.
NPJ Regen Med
. 2024 Sep;
9(1):22.
PMID: 39289387
Local injection of anti-inflammatory drugs for osteoarthritis emerged as a promising administration in the clinic, and sustained-release dosage forms have great potential for future therapeutic applications. Controlling the response of...
6.
Fu X, Shi Y, Gu Z, Zang H, Li L, Wang Q, et al.
Asian J Pharm Sci
. 2024 Jul;
19(3):100925.
PMID: 38966285
Despite standard treatment for non-small cell lung cancer (NSCLC) being surgical resection, cancer recurrence and complications, such as induction of malignant pleural effusion (MPE) and significant postoperative pain, usually result...
7.
Wang W, Liu M, Fu X, Qi M, Zhu F, Fan F, et al.
Phytomedicine
. 2024 Jun;
132:155814.
PMID: 38878526
Alcohol-associated liver disease (ALD) is a prevalent liver ailment. It has escalated into a significant public health issue, imposing substantial burdens on medical, economic, and social domains. Currently, oxidative stress,...
8.
Qi M, Chu S, Wang W, Fu X, Jiang C, Zhang L, et al.
Biomed Pharmacother
. 2024 Apr;
174:116553.
PMID: 38593703
This study is to investigate the effect of SPS on the UC model. An animal model of UC induced by DSS was developed using C57BL/6 mice. The body weight was...
9.
Qiu S, Fu X, Shi Y, Zang H, Zhao Y, Qin Z, et al.
Mol Pharm
. 2023 Jun;
20(8):3947-3959.
PMID: 37358639
Idiopathic pulmonary fibrosis (IPF) causes worsening pulmonary function, and no effective treatment for the disease etiology is available now. Recombinant Human Relaxin-2 (RLX), a peptide agent with anti-remodeling and anti-fibrotic...
10.
Liu N, Liu M, Jiang M, Li Z, Chen W, Wang W, et al.
Biomed Pharmacother
. 2023 Jan;
159:114173.
PMID: 36680814
The study aimed to investigate the effect of isoliquiritigenin (ISL) on model of alcoholic liver fibrosis (ALF). C57BL/6 mice were used to establish animal model of ALF, HSC-T6 cells were...